FEATURED NEWS
Reminder: 4 days to Brexit Event!
Our CEO Ann McGee will be speaking at the Pharma and Brexit Conference – hosted by PDA Ireland and PDA United Kingdom.
The event will focus on the impact, challenges and solutions for the pharmaceutical industry.
Reminder: 4 days to BREXIT Event!
Our CEO Ann McGee will be speaking at the Pharma and Brexit Conference - hosted by PDA Ireland and PDA United Kingdom. The event will
We Welcome our New CEO Pierre-Henri Baviera
We are very excited to announce the appointment of Pierre-HenriBaviera as the new CEO for Mias Pharma Limited. As an experienced
Upcoming Shows
MIAS Pharma will be attending the following events in the coming months: 35th Annual Congress of the European Association of Nuclear
MHRA (GxP) Inspections during COVID19
The COVID19 pandemic presents an unprecedented challenge to healthcare, the pharmaceutical industry’s supply chain and personnel movement. MHRA understands the impact of its work
We Welcome our New CEO Pierre-Henri Baviera
We are very excited to announce the appointment of Pierre-HenriBaviera as the new CEO for Mias Pharma
Upcoming Shows
MIAS Pharma will be attending the following events in the coming months: 35th Annual Congress of the
Annex 21 in Effect from August 21st 2022
The new Annex 21, The Rules Governing Medicinal Products in the European Union Volume 4 EU Guidelines
Brexit and the Evolving Impact on the Pharmaceutical World
Brexit took place at 11pm on 31 Jan 2020 as the UK departed from the European Union. A transition period of 11 months began
New QTA requirements with Importation Site
The manufacture of pharmaceutical products for the EU, including active substances and medicinal products, frequently occurs outside of the Union. As required by the
EMA Reflection Paper on GMP & MAHs – considerations for QPs
In July 2021, the European Medicines Agency (EMA) published the final reflection paper entitled "Good Manufacturing Practice and the Marketing Authorisation Holder" after a